drug pricing

Pharmalot By Ed Silverman

Advocates urge Biden to name patent office director that could transform drug pricing

Pharmalot By Ed Silverman

Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug

Pharmalot By Ed Silverman

U.K. issues record fine to drug makers for price gouging and collusion schemes

Politics By Rachel Cohrs

Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal

D.C. Diagnosis By Nicholas Florko

Are pharma mergers bad for biotech?

Pharmalot By Ed Silverman

U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing

Pharmalot By Ed Silverman

Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year

Pharmalot By Ed Silverman

‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism

First Opinion By James K. Glassman

Biden won’t end cancer — or any other disease — by importing drug price controls from Europe

Politics By Rachel Cohrs and Emory Parker

Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?

Pharmalot By Ed Silverman

In an about-face, Health Canada allows a controversial rare disease drug back on the market

Politics By Rachel Cohrs

House leaders to investigate FDA approval and price of Biogen’s Alzheimer’s drug 

Pharmalot By Ed Silverman

As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat black fungus in recovering patients

Pharmalot By Ed Silverman

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

Pharmalot By Elizabeth Cooney

Pharmalittle: Inside the FDA’s contentious Aduhelm approval; Peter Bach heading to liquid biopsy startup

Politics By Nicholas Florko

Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs

Pharmalot By Ed Silverman

Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between

Politics By Nicholas Florko

BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights 

Pharmalot By Ed Silverman

HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies

Pharmalot By Ed Silverman

A California law that bans drug coupons failed to increase generic use

Pharmalot By Ed Silverman

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

Pharmalot By Ed Silverman

Centene to pay $143 million to two states to settle allegations of overcharging Medicaid

Politics By Rachel Cohrs

Biden administration moves to axe Trump 340B rule targeting community clinics

Pharmalot By Ed Silverman

Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin

Pharmalot By Ed Silverman

‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine